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Objective The aim of this study was to evaluate the effect
of trandolapril, an angiotensin converting enzyme inhibitor,
on blood pressure, forearm blood ¯ow and insulin
sensitivity in comparison with nifedipine gastrointestinal
therapeutic system.
Patients and methods This is a multicentre, two-way
parallel-group, open-label comparative study in 90
overweight hypertensive patients, who were randomly
assigned to treatment for 8 weeks with either trandolapril
or nifedipine. At baseline and after treatment, all patients
underwent an oral glucose tolerance test, an evaluation of
their metabolic pro®les and a euglycaemic
hyperinsulinaemic clamp test. In a subgroup of 18 patients,
a forearm study was carried out.
Results Blood pressure fell by the second week of
treatment and remained signi®cantly reduced compared
with baseline in both treatment groups. Plasma triglyceride
levels were also signi®cantly reduced after trandolapril
therapy, but no signi®cant changes occurred in the other
metabolic parameters during treatment with either drug.
During the euglycaemic hyperinsulinaemic clamp, whole-
body glucose use was similar in the two treatment groups
at baseline, and a moderate but statistically signi®cant
increase in insulin sensitivity was observed after
trandolapril treatment (trandolapril: 5.0  0.2 versus
4.5  0.2 mg=kg per min; nifedipine: 4.1  0.3 versus
4.2  0.3 mg=kg per min; P , 0.05, versus baseline
and trandolapril versus nifedipine treatment). Skeletal
muscle glucose uptake was signi®cantly higher after
trandolapril than after nifedipine therapy (5.0  0.7 and
3.0  0.4 mg=min, respectively; P , 0.01). As forearm
blood ¯ow was similar in the two treatment groups at
baseline and was unchanged after 8 weeks of therapy,
skeletal muscle glucose extraction was signi®cantly
greater in the ACE inhibitor treated-group than in the
nifedipine comparative group (trandolapril: baseline
21  2, treatment 24  3 mg=dl; nifedipine: baseline
18  3, treatment 16  2 mg=dl; P , 0.05, trandolapril
versus nifedipine treatment).
Conclusions During short-term treatment, ACE inhibition
with trandolapril was able to moderately improve insulin
sensitivity, in comparison with calcium blockade, and this
effect appeared to be independent of the haemodynamic
action of the drug. J Hypertens 1999, 17:439±445 &
Lippincott Williams & Wilkins.
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Introduction
Essential hypertension is very often associated with
metabolic abnormalities which are powerful risk factors
for coronary heart disease [1], and insulin resistance
appears to be a key factor in this association [2±5].
Failure to effectively control these metabolic correlates
of hypertension may be one of the reasons why
antihypertensive treatment achieved less than the ex-
pected bene®t in some intervention trials. In recent
years, increasing attention has been focused on the
metabolic effects of commonly used antihypertensive
drugs [6,7]. It appears that antihypertensive therapy is
best tailored to the individual patient, and that in
patients with concomitant metabolic abnormalities,
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antihypertensive drugs with adverse metabolic effects
should be avoided [8].
The metabolic pro®le of the most effective antihyper-
tensive drugs has been investigated extensively [8].
Although it is clear that calcium blockers are metaboli-
cally neutral [5,9±12], there is still debate over the
question of whether angiotensin converting enzyme
(ACE) inhibitors can ameliorate insulin sensitivity [13±
31].
To investigate this question, we set up a randomized
trial to determine the effects of the ACE inhibitor
trandolapril on blood pressure and insulin sensitivity in
comparison with nifedipine gastrointestinal therapeutic
system (GITS). Since peripheral vasodilation allows a
greater supply of glucose and insulin to skeletal muscle,
and has been proposed as a possible mechanism for the
putative effect of ACE inhibition on insulin sensitivity,
we also evaluated regional blood ¯ow and insulin-
stimulated glucose uptake by forearm skeletal muscle
in a subgroup of patients during short-term treatment
with the two study drugs.
Patients and methods
Study design and patient selection
The study followed a multicentre, randomized, two-
way parallel-group, open-label comparative design. Five
centres participated, and all obtained approval from the
local ethical committees. The study population con-
sisted of patients with mild or moderate essential
hypertension referred to outpatient clinics, and all gave
informed consent. Entry criteria included age 35±65
years, blood pressure consistently over 140 mmHg
systolic and/or 90 mmHg diastolic on three consecutive
visits and a body mass index (BMI) of 25±30 kg=m2.
Patients with congestive heart failure, cardiac or cere-
brovascular disease, known diabetes or a plasma creati-
nine concentration greater than 140 ìmol=l were
excluded. Ninety patients who met the above criteria
entered a 2 week wash-out period, during which any
antihypertensive treatment was withdrawn, followed by
2 weeks of placebo administration (single daily cap-
sule). At the end of this period, the patients were
randomly assigned to active treatment for 8 weeks with
either 2 mg trandolapril (Gopten; Knoll, MuggioÁ , MI,
Italy) or 30 mg nifedipine-GITS (Adalat Crono 30;
Bayer, Milan, Italy) every morning at 8 a.m.
Blood pressure was measured at the end of the placebo
run-in period, after 2 and 5 weeks of therapy and at the
end of the treatment period. At the end of the placebo
run-in and after the 8-week treatment period, venous
blood was collected for the evaluation of fasting serum
glucose, insulin, total and high-density lipoprotein
(HDL) cholesterol and triglyceride levels; an oral glu-
cose tolerance test and a euglycaemic hyperinsulinae-
mic clamp test were carried out; and a forearm study
was performed in a subgroup of 18 patients (nine taking
trandolapril and nine taking nifedipine-GITS).
Oral glucose tolerance test
The oral glucose tolerance test was performed by
administering a standard load of 75 g glucose, in the
morning after a 12 h fast. A venous blood sample was
obtained before and 60 and 120 min after the glucose
load for measurement of glucose and insulin concentra-
tions. Glucose tolerance was de®ned according to
National Diabetes Data Group criteria [32].
Euglycaemic hyperinsulinaemic clamp
After a 12 h overnight fast, a polyethylene cannula was
inserted into an antecubital vein for insulin and glucose
infusion. A second cannula was placed retrogradely into
a hand vein for intermittent blood sampling, the hand
being warmed in a heated box (608C) to ensure
arterialization of venous blood. Regular insulin was
administered intravenously at a constant rate of
1:2 mU=kg body weight per min for 2 h to induce a
physiological increase in peripheral insulin concentra-
tion. A solution of 20% glucose in water was infused
simultaneously to maintain the blood glucose concen-
tration at its basal level. The glucose infusion rate was
adjusted according to plasma glucose levels, which were
measured every 5 min with a Beckman glucose analyser
(Beckman Instruments, Fullerton, California, USA).
Blood samples for insulin measurements were taken in
the basal state immediately before the clamp and every
40 min during the clamp. The amount of glucose
infused to maintain euglycaemia is considered equal to
the amount of glucose metabolized, provided hepatic
glucose production is totally suppressed. Although we
did not measure hepatic glucose output in our patients,
previous studies have shown that the insulin-inhibitory
effect of hepatic glucose output is well preserved in
hypertensive patients [2], and that at insulin concentra-
tions similar to those achieved in our study, hepatic
glucose output is completely suppressed [2]. We there-
fore assumed that in our study patients, the glucose
infusion rate during the last 40 min of the clamp
represented whole-body glucose disposal and this meas-
urement was taken as an index of insulin sensitivity.
Forearm study
A te¯on catheter was introduced retrogradely into a
large antecubital vein and threaded as deeply as
possible (under these conditions, the ef¯uent venous
blood predominantly drains muscle tissue). A second
catheter was inserted into the ipsilateral brachial artery
for blood sampling and for infusion of indocyanine
green dye (Cardio-Greeen; Westcott of Dunning, Balti-
more, Maryland, USA) to measure blood ¯ow. Insulin
and glucose were infused through a contralateral vein,
and simultaneous blood samples were taken from the
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arterial and the deep-venous catheter every 40 min for
2 h. Five minutes before each blood collection, a
sphygmomanometer cuff placed around the wrist was
in¯ated 100 mmHg above the arterial blood pressure to
exclude the hand from the circulation. Soon after blood
collection, indocyanine green dye was infused through
the arterial catheter, while keeping the cuff in¯ated
around the wrist. After 5 min, two venous blood sam-
ples were taken, at 1 min intervals, to measure the
plasma concentration of the dye.
Biochemical measurements
All biochemical measurements were carried out in the
laboratories of the Department of Clinical and Experi-
mental Medicine, Federico II University of Naples.
Plasma glucose was measured by the glucose-hexokin-
ase method using a Cobas-Mira spectrophotometer
(Roche, Basel, Switzerland). Plasma insulin was meas-
ured by radioimmunoassay, using a commercially avail-
able kit (Techno Genetics, Milan, Italy). Lipids were
measured by enzymatic-colorimetric methods using a
Cobas-Mira spectrophotometer (Roche).
Calculations and de®nitions
Mean blood pressure was calculated as [one-third
(systolic minus diastolic blood pressure) plus diastolic
blood pressure]. BMI was calculated as weight
(kg)=height (m2). Insulin-induced whole-body glucose
uptake was calculated as mg glucose infused per kg
body weight per min, during the last 40 min of the
clamp. Forearm plasma ¯ow was estimated by dividing
the dye infusion rate by its concentration in venous
plasma, and converted to blood ¯ow (ml=min) accord-
ing to haematocrit levels. The forearm glucose uptake
was calculated by multiplying the arteriovenous glucose
difference by forearm blood ¯ow, and was normalized
to the forearm volume in litres. Forearm glucose uptake
in response to insulin was measured as the mean of two
observations taken after 80 and 120 min of the clamp.
Insulin-stimulated glucose clearance was calculated as
insulin-induced whole-body glucose uptake divided by
the mean plasma glucose level during the last 40 min of
the clamp, normalized to the concomitant plasma
insulin concentration [13].
Statistics
Statistical analysis was performed using the Statistical
Package for the Social Sciences. One-way analysis of
variance was used to detect possible differences be-
tween the two therapies. Two-tailed Student's paired t
test was used to compare the differences between
baseline and the end of the treatment period. Data are
expressed as means  SEM.
Results
The two treatment groups were fully comparable at
baseline with regard to sex distribution, age, BMI,
fasting plasma glucose and plasma insulin levels, total
cholesterol and HDL cholesterol and triglyceride levels
(Table 1). Blood pressure was similar at the end of the
placebo run-in period in the two groups, fell to a similar
extent by the second week of treatment and remained
signi®cantly reduced compared with baseline in both
groups (Fig. 1). No signi®cant changes occurred in any
anthropometric or metabolic parameters during treat-
ment with either drug, except that serum triglyceride
concentrations were signi®cantly lower after trandola-
pril therapy (Table 1). Table 2 gives the results of the
oral glucose tolerance test performed before and after
treatment with each drug. There was a trend for an
improvement in glucose tolerance after trandolapril
therapy, as glucose levels were 9% lower in the
presence of plasma insulin concentrations similar to
baseline values. This difference in blood glucose re-
sponse to the oral glocose tolerance test was of border-
line signi®cance.
Euglycaemic hyperinsulinaemic clamp
The basal glucose level was 4.89  0.10 and
4.84  0.10 mmol=l for the trandolapril group before
and after treatment, respectively, and 5.06  0.10 and
5.11  0.10 mmol=l for the nifedipine group. These
values remained virtually unchanged during the clamp.
The coef®cient of variation for blood glucose during
Table 1 Anthropometric and metabolic data of overweight hypertensive patients by treatment group
at baseline and at the end of treatment
Trandolapril Nifedipine
Baseline During treatment Baseline During treatment
n (males=females) 45 (26=19) 45 (28=17)
BMI (kg=m2) 28.4  0.3 28.4  0.3 28.6  0.3 28.7  0.3
IRI (ìU=ml) 9.4  0.8 10.8  1.8 10.9  2.0 10.1  0.6
GLU (mmol=l) 4.88  0.11 4.94  0.11 5.05  0.11 4.99  0.11
CHOL (mmol=l) 5.61  0.15 5.66  0.15 5.66  0.15 5.74  0.15
TG (mmol=l) 1.40  0.10 1.34  0.08y 1.44  0.13 1.53  0.13
HDL (mmol=l) 1.11  0.05 1.14  0.05 1.09  0.05 1.14  0.05
Values are means  SEM. BMI, body mass index; IRI, immunoreactive insulin; GLU, glucose; CHOL, cholesterol; TG,
triglycerides; HDL, high-density lipoprotein cholesterol. P , 0.05, versus baseline; yP , 0.01, versus nifedipine.
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the clamp was 8%. Plasma insulin concentrations were
comparable before the clamp in the two treatment
groups (baseline 10  1 and 11  2 ìU=ml; during
treatment 10  2 and 10  1 ìU=ml, for the trandolapril
and nifedipine groups, respectively) and increased to a
similar extent during the clamp (trandolapril group:
47  2 and 49  2 ìU=ml; nifedipine group: 46  2 and
47  2 ìU=ml, before and after treatment, respect-
ively). As shown in Figure 2, whole-body glucose use
during the last 40 min of the clamp was not different in
the two treatment groups at baseline. After trandolapril
treatment, a signi®cant increase in insulin sensitivity
was observed in comparison with baseline and with
nifedipine-GITS therapy (Fig. 2). When the data were
expressed in terms of mean insulin-stimulated glucose
clearance, the increase in plasma insulin sensitivity was
still signi®cantly higher for the trandolapril group com-
pared with baseline (1.31  0.11 versus 1.16 
0.08 ml=min per kg, P , 0.05) or with nifedipine treat-
ment (increase in insulin-stimulated glucose clearance:
0.15  0.07 versus 0.02  0.1 ml=min per kg, P , 0.05).
A signi®cant inverse correlation was detected in the
group as a whole between changes in insulin sensitivity
and concomitant changes in serum triglyceride concen-
trations (r  ±0.27, P , 0.02), an improvement in in-
sulin sensitivity being associated with a fall in serum
triglyceride levels. A trend towards a reciprocal associa-
tion between the improvement in insulin sensitivity
and the blood glucose response to the oral glucose
tolerance test was also apparent (r  ÿ0.30), but did
not reach statistical signi®cance.
Forearm study
Skeletal muscle blood ¯ow was similar in the two
treatment groups, both at baseline and after 8 weeks of
therapy, and remained unaltered in response to an
infusion of insulin (Table 3). As the drug-induced
blood pressure fall was comparable in the two groups,
we conclude that vascular resistance was reduced to the
same extent with each drug. Insulin-stimulated glucose
uptake was signi®cantly higher after trandolapril than
after nifedipine treatment (5.0  0.7 versus 3.0 
0.4 mg=min, respectively, P , 0.01). This indicates that
skeletal muscle glucose extraction was greater after
trandolapril treatment, as forearm glucose uptake is
calculated by multiplying the arteriovenous glucose
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Systolic (tops of bars) and diastolic (bottoms of bars) blood pressure
before and during therapy. wks, Weeks. P , 0.0001, versus baseline
(0).
Table 2 Plasma insulin and glucose levels during oral glucose tolerance test, by treatment group
Trandolapril Nifedipine
0 min 60 min 120 min 0 min 60 min 120 min
Glucose (mmol=l)
Basal 4.99  0.11 8.11  0.33 5.72  0.33 5.05  0.11 8.44  0.39 5.83  0.22
On therapy 4.89  0.11 7.55  0.33 5.77  0.28 4.94  0.11 8.55  0.39 5.77  0.28
Insulin (ìU/ml)
Basal 9  1 54  6 39  8 11  1 68  7 50  8
On therapy 10  1 54  3 42  5 10  1 68  8 44  6
Values are means  SEM.
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Fig. 2
Insulin-stimulated whole-body glucose use in the two treatment groups.
White bars represent values at the end of placebo run-in period and
shaded bars represent values during treatment. M, mg glucose infused
per kg body weight per min during the last 40 min of the clamp.P , 0.05, versus baseline; P , 0.05, versus nifedipine.
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extraction by the forearm blood ¯ow. Insulin infusion,
as expected, remarkably increased forearm glucose
extraction in both groups, both before and during
treatment (Fig. 3). However, while no signi®cant differ-
ence in the effect of insulin was detectable between
the two groups at baseline, at the end of the 8 week
treatment period, the effect of insulin infusion was
signi®cantly greater in the ACE inhibitor-treated group
than in the nifedipine comparative group (Fig. 3).
Discussion
A number of studies have investigated the metabolic
effects of ACE-inhibiting drugs, with a particular focus
on insulin sensitivity [13±31]. The results of these
studies are generally controversial. Many of them used
less sensitive methods for detecting insulin sensitivity
and largely found no effect of ACE inhibitors on
glucose metabolism [16±22], with the exception of two
studies [14,15] that suggested a positive effect. Among
the trials that used the euglycaemic hyperinsulinaemic
clamp for the measurement of insulin sensitivity
[13,23±31], only eight were placebo-controlled or com-
parative studies (versus other antihypertensive drugs).
The results of one of these studies were not conclusive
due to a carryover effect from previous antihyperten-
sive medications [24], while others found that ACE
inhibitors improved insulin sensitivity during both
short- [25,26] and longer-term treatment [27,28].
In a comparison of the effects of ACE inhibition with
á1-adrenergic blockade, both classes of drugs ameli-
orated insulin sensitivity, although the effect was great-
er for the á1-adrenergic blocker doxazosin [29±30]. Yet
another study of different ACE inhibitor drugs sug-
gested that this class of drugs has a generally favourable
effect on insulin sensitivity, although the effect varied
with different drugs [31].
The present study, which included the largest patient
population so far, showed that trandolapril and nifedi-
pine-GITS had signi®cantly different effects on whole-
body insulin sensitivity for a similar blood pressure fall.
The improvement in insulin sensitivity with the ACE
inhibitor was relatively small in absolute terms, yet is
probably biologically meaningful given that the study
patients had only a modest degree of insulin resistance
overall in the absence of severely obese and diabetic
individuals. The effect of ACE inhibition on insulin-
stimulated whole-body glucose uptake was associated
with an improvement in glucose tolerance of borderline
signi®cance and with a statistically signi®cant fall in
serum triglyceride levels. Furthermore, a low-grade but
statistically signi®cant correlation was seen between the
changes in triglyceride levels and those in whole-body
glucose uptake.
Although the study design did not include a placebo
control, it is clear that ACE inhibition ameliorated
insulin resistance in comparison with nifedipine-GITS
therapy. This conclusion is clinically relevant because
the bulk of the available evidence supports the meta-
bolic neutrality of calcium blockers in hypertensive
patients.
The very least that can be said for the ameliorative
effect of trandolapril on insulin sensitivity is that its
vasodilating potential presumably leads to an increase
in glucose and insulin supply to skeletal muscle or
visceral organs as a consequence of increased blood
¯ow [16,33]. Nevertheless, the concomitant observation
Table 3 Forearm blood ¯ow (ml/l per min) during euglycaemic hyperinsulinaemic clamp, by
treatment group
Baseline During treatment
0 min 40 min 80 min 120 min 0 min 40 min 80 min 120 min
Trandolapril 22  1 25  2 26  2 24  2 22  2 22  1 22  2 21  2
Nifedipine 24  2 22  2 23  2 21  2 19  2 19  2 20  3 20  2
Values are means  SEM.
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Fig. 3
Effect of insulin on forearm glucose balance before (white bars) and
after 8 weeks of therapy (shaded bars) in the two treatment groups.P , 0.05, versus corresponding nifedipine value.
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that during short-term treatment with both drugs, no
substantial changes in blood ¯ow to foream skeletal
muscle were detected either under basal conditions or
during the hyperinsulinaemic state appears to detract
from this hypothesis. In this respect, our ®ndings are in
line with a report by Santoro et al. [13] that after 7 days
of ACE inhibition there was a signi®cant fall in blood
pressure but no change in forearm blood ¯ow, and with
a study by Bijlstra et al. [34], who found that the
forearm blood ¯ow response to endothelium-dependent
vasodilation was unaffected by 6 months of ACE
inhibition in diabetic patients. Several other studies
dealing with a possible direct vasodilating effect of
insulin have provided controversial results [35±40]. In
particular, our ®nding that peripheral blood ¯ow did
not increase during systemic hyperinsulinaemia is in
agreement with reports by DeFronzo et al. [35] and
Natali et al. [36]. Our present data suggest that the
improvement in whole-body insulin-mediated glucose
use during ACE inhibition was associated with in-
creased forearm skeletal muscle glucose extraction in
comparison with calcium blockade, independently of
changes in regional blood ¯ow. This ®nding is in
keeping with results reported by Jacob et al. [41], who
assessed skeletal muscle glucose metabolism in obese
Zucker rats without the potentially confounding in¯u-
ence of changes in blood ¯ow, by using an isolated
epitrochlearis muscle preparation. These authors [41]
reported that during both short- and long-term adminis-
tration, trandolapril improved the activity of the insu-
lin-sensitive transport system GLUT-4 in insulin-
resistant skeletal muscle. Similarly, in insulin-resistant
obese rats, both the ACE inhibitor captopril and
trandolapril increased glucose transport [42] and insu-
lin-stimulated 2-deoxyglucose uptake by isolated skele-
tal muscle [43]. It is clear that further investigation is
needed to elucidate the cellular mechanisms respons-
ible for the improvement in skeletal muscle insulin
action following ACE inhibitor treatment.
In conclusion, the present study shows that the ACE
inhibitor trandolapril improved insulin sensitivity to a
moderate degree in comparison with calcium blockade
during short-term treatment in hypertensive patients
with low-grade insulin resistance. This effect appeared
to be independent of the haemodynamic action of the
ACE inhibitor and was perhaps related to a direct effect
of trandolapril on insulin-sensitive glucose metabolism
in skeletal muscle.
Appendix: The TRIS Study Group
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